期刊文献+

8例Richter综合征临床及生物学特征分析 被引量:3

Clinical and Biological Features of 8 Patients with Richter's Syndrome
下载PDF
导出
摘要 为了探讨Richter综合征(RS)临床及生物学特征及其预后因素,回顾性分析8例RS患者。利用血清学检测、多参数流式细胞术(FCM)、常规细胞遗传学(CC)、间期荧光原位杂交(FISH)技术、PCR联合DNA序列测定,分别检测患者血清乳酸脱氢酶(LDH)、β2-微球蛋白(β2-MG)、胸苷激酶1(TK1)、血清铁蛋白(SF)和糖链抗原-125(CA-125),CD38和ZAP-70,染色体核型,ATM和p53基因缺失、+12异常,以及免疫球蛋白重链可变区(IgVH)突变。结果显示:8例RS患者中7例转化为弥漫大B细胞淋巴瘤(DLBCL),1例转化为霍奇金淋巴瘤(HL)。7例LDH高于正常值,4例β2-MG高于正常值,7例SF高于正常值,4例CA-125高于正常值,1例TK1高于正常值。4例患者ZAP-70阳性,7例CD38阳性,5例IgVH无突变,4例有染色体复杂核型,1例有+12,1例有p53缺失。按就诊时BinetA+B期与BinetC期将患者分为两组,BinetA+B组从诊断至转化的平均时间为98.5个月,BinetC组为38.3个月,两组间有显著性差异(p=0.021)。平均总生存期(OS)在BinetA+B组及BinetC组之间分别是123.8个月及49.8个月,两组间有显著性差异(p=0.049),转化后平均生存时间分别是34.5个月及10.3个月。结论:RS患者血清LDH、β2-MG和SF水平高,ZAP-70和CD38高表达、IgVH无突变发生率高,临床分期可能是RS转化的风险及预后因素。 In order to evaluate the clinical,biological features and prognostic factors of Richter's syndrome(RS),8 RS patients were analyzed restrospectively. The serological test,multiplex parameter flow cytometry,conventional cytogenetic analysis,FISH technique and PCR combined with sequence detection were used to detect the LDH,β2-MG,TK1,SF,CA125,ZAP-70,chromosome karyotype,ATM and p53 gene deletion,as well as +12 abnormality and IgVH mutation. The results indicated that 7 out of 8 patients transformed to diffuse large B cell lymphoma (DLBCL) and 1 patient transformd to Hodgkin lymphoma (HL). Among 8 patients,LDH level in 7 patients,β2-MG level in 4 patients,SF level in 7 patients,CA-125 level in 4 patients and TK1 level in 1 patient exceeded the normal range. Meanwhile,ZAP-70 and CD38 were expressed positively in 4 and 7 out of 8 patients respectively. Unmutated IgVH was found in 5 patients,and 4 patients had the complex chromosome abnormalities. +12 and p53 deletion was found in 1 patient. 8 patients were divided into two groups (Binet A+B and Binet C),the mean time from diagnosis to progression was 98.5 months in Binet A+B group,compared with 38.3 months in Binet C group,there was significant difference between two groups(p=0.021). Mean overall survival was 123.8 months and 49.8 months in two groups,respectively (p=0.049). The mean survival after transformation was 34.5 months in Binet A+B group and 10.3 months in Binet C group. In conclusion,the level of LDH,β2-MG and SF are higher in RS patients in Binet C group,and so are the incidence of high expressed ZAP-70 and CD 38,unmutated IgVH. The clinical stage may be the risk and prognostic factors for RS transformation.
出处 《中国实验血液学杂志》 CAS CSCD 2010年第6期1499-1504,共6页 Journal of Experimental Hematology
基金 国家自然基金资助项目(30871104) 江苏省医学领军人才基金资助项目(LJ200623) 江苏省医学重点人才基金资助项目(RC2007042) 江苏省自然基金基助项目(BK2007249)
关键词 慢性淋巴细胞白血病 Richter's综合征 非霍奇金淋巴瘤 霍奇金淋巴瘤 chronic lymphocytic leukemia Richter′s sydrome non Hodgkin′s lymphoma Hodgkin′s lymphoma
  • 相关文献

参考文献16

  • 1郑文娟,陈丽娟,吴雨洁,李丽,徐卫,李建勇.应用多重PCR技术检测慢性淋巴细胞白血病IgVH基因突变[J].中国实验血液学杂志,2006,14(6):1101-1104. 被引量:8
  • 2顾卫军,徐卫,钱思轩,吴雨洁,洪鸣,陈丽娟,吴汉新,陆化,仇红霞,李建勇.利妥昔单克隆抗体联合氟达拉滨及环磷酰胺治疗慢性淋巴细胞白血病[J].中国实验血液学杂志,2008,16(4):938-942. 被引量:8
  • 3Tsimberidou AM, Keating MJ. Richter syndrome: biology, inci- dence, and therapeutic strategies. Cancer, 2005 ; 103 (2) :216 - 228.
  • 4Tsimberidou AM, O'Brien S, Kantarjian HM, et al. Hodgkin trans- formation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer, 2006 ; 107 ( 6 ) : 1294 - 1302.
  • 5Yamazaki ML, Lum CA, Izumi AK. Primary cutaneous Richter syn-drome: prognostic implications and review of the literature. J Am Acad Dermatol, 2009 ;60( 1 ) : 157 - 161.
  • 6Robak E, Gora-Tybor J, Kordek R, et al. Richter syndrome first manifesting as cutaneous B-cell lymphoma clonally distinct from pri- mary B-cell chronic lymphocytic leukaemia. Br J Dermatol, 2005; 153(4) :833 -837.
  • 7Ghofrani M, Tantiwongkosi B, Smith AS, et al. Richter transforma- tion of chronic lymphocytic leukemia presenting as a dural-based non- hodgkin lymphoma mass. AJNR Am J Neuroradiol, 2007 ; 28 ( 2 ) : 318 -320.
  • 8Denier C, Tertian G, Ribrag V, et al. Muhifocal deficits due to leu- kemic meningoradicuIitis in chronic lymphocytic leukemia. J Neurol Sci, 2009 ;277 ( 1 - 2 ) : 130 - 132.
  • 9Swords R, Bruzzi J, Giles F. Recent advances in the diagnosis and therapy of Richter's syndrome. Med Oncol, 2007 ;24 ( 1 ) : 17 - 32.
  • 10Shackelford RE, Bhalodia AR, Cotehngam JD, et al. Increased transferrin receptor expression following 11 q23 deletion as a mecha- nism of malignant progression in chronic lymphocytic leukemia. Med Hypotheses, 2006 ;66 ( 3 ) :509 - 512.

二级参考文献22

  • 1徐卫,李建勇,潘金兰,仇海荣,沈云锋,肖冰,陈丽娟,吴亚芳,盛瑞兰,薛永权.慢性淋巴细胞白血病的分子遗传学特点[J].中华肿瘤杂志,2006,28(5):349-352. 被引量:13
  • 2李丽,徐卫,李建勇.慢性淋巴细胞白血病预后因素研究进展[J].中华内科杂志,2006,45(9):781-783. 被引量:17
  • 3李丽,徐卫,仇海荣,程月新,张苏江,李建勇.探针D13S319和D13S25检测慢性淋巴细胞白血病13q14缺失[J].中国实验血液学杂志,2007,15(2):229-232. 被引量:8
  • 4Shanafelt TD,Geyer SM,Kay NE.Prognosis at diagnosis:integrating molecular biologic insights into clinical practice for patients with CLL.Blood,2004;103:1202-1210
  • 5Chiorazzi N,Rai KR,Ferrarini M.Chronic lymphocytic leukemia.N Engl J Med,2005;352:804-815
  • 6Hamblin TJ,Davis Z,Gardiner A,et al.Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.Blood,1999;94:1848-1854
  • 7Damle RN,Wasil T,Fais F,et al.Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.Blood,1999;94:1840-1847
  • 8Montillo M,Hamblin T,Hallek M,et al.Chronic lymphocytic leukemia:novel prognostic factors and their relevance for risk-adapted therapeutic strategies.Haematologica,2005;90:391-399
  • 9van Dongen JJM,Langerak AW,Bruggemann M,et al.Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations:Report of the BIOMED-2 Concerted Action BMH4-CT98-3936.Leukemia,2003;17:2257-2317
  • 10Tobin G,Thunberg U,Johnson A,et al.Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia.Blood,2002;99:2262-2264

共引文献14

同被引文献14

  • 1Maddocks-Christianson K, Slager SL, Zent CS, et al. Risk factors for development of a second malignancy in patients with chronic lym- phocytic leukemia. Br J Haematol, 2007; 139 (3) :398 -404.
  • 2Rossi D, Cerri M, Capello D, et al. Biological and clinical risk fac- tors of chronic lymphocytic leukaemia transformation to Richter syn- drome. Br J Haematol, 2008;142(2) :202 -215.
  • 3Bea S, Lopez-Guillermo A, Ribas M, et al. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). Am J Pathol, 2002;161 ( 3 ) :957 - 968.
  • 4Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzum- ab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the german chronic lymphocytic leukemia study group. J Clin Oncol, 2009 ; 27 ( 24 ) : 3994 - 4001.
  • 5Tsimberidou AM,Keating MJ. Richter syndrome:biology,incidence,and therapeutic strategies[J].Cancer,2005,(02):216-228.
  • 6Swords R,Bruzzi J,Giles F. Recent advances in the diagnosis and therapy of Richter's syndrome[J].Medical Oncology,2007,(01):17-32.
  • 7Shackelford RE,Bhalodia AR,Cotelingam JD. Increased transferrin receptor expression following 11q23 deletion as a mechanism of malignant progression in chronic lymphocytic leukemia[J].Medical Hypotheses,2006,(03):509-512.
  • 8Rossi D,Cerri M,Capello D. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome[J].British Journal of Haematology,2008,(02):202-215.
  • 9Josting A,Wiedenmann S,Franklin J. Secondary myeloid leukemia and melodys plastic syndromes in patients treated for Hodgkins disease:a report from the German Hodgkins Lymphoma Study Group[J].Journal of Clinical Oncology,2003,(18):3440-3446.
  • 10Bruzzi JF,Macapinlac H,Tsimberidou AM. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT[J].The Journal of Nuclear Medicine,2006,(08):1267-1273.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部